These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26417203)

  • 1. Everolimus in the Treatment of Metastatic Breast Cancer.
    Royce ME; Osman D
    Breast Cancer (Auckl); 2015; 9():73-9. PubMed ID: 26417203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer.
    Sobhani N; Generali D; Zanconati F; Bortul M; Scaggiante B
    World J Clin Oncol; 2018 Dec; 9(8):172-179. PubMed ID: 30622925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
    O'Shaughnessy J; Thaddeus Beck J; Royce M
    Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
    Rugo HS
    Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
    Barnett CM
    Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer.
    Beck JT
    Onco Targets Ther; 2015; 8():3629-38. PubMed ID: 26675495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.
    Paplomata E; O'Regan R
    Ther Clin Risk Manag; 2013; 9():27-36. PubMed ID: 23345981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
    Ng VC; Johnson JJ; Cuellar S
    J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
    BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
    Royce M; Bachelot T; Villanueva C; Özgüroglu M; Azevedo SJ; Cruz FM; Debled M; Hegg R; Toyama T; Falkson C; Jeong J; Srimuninnimit V; Gradishar WJ; Arce C; Ridolfi A; Lin C; Cardoso F
    JAMA Oncol; 2018 Jul; 4(7):977-984. PubMed ID: 29566104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases.
    Beck JT; Mantooth R
    Case Rep Oncol; 2015; 8(1):101-5. PubMed ID: 25848360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer.
    Saksena R; Wong ST
    Breast Cancer (Dove Med Press); 2013; 5():27-35. PubMed ID: 24648755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.
    Yi Z; Ma F
    J Breast Cancer; 2017 Dec; 20(4):321-326. PubMed ID: 29285035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.
    Sun B; Ding L; Wu S; Meng X; Song S
    Onco Targets Ther; 2016; 9():3997-4003. PubMed ID: 27445490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
    Gilabert M; Launay S; Gonçalves A
    Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus in the treatment of hormone receptor-positive breast cancer.
    Chavez-MacGregor M; Gonzalez-Angulo AM
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1835-43. PubMed ID: 22994502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
    Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.